Target type: molecularfunction
Catalysis of the reaction: 20-oxo-leukotriene B4 + O2 + reduced [NADPH-hemoprotein reductase] = 20-carboxy-leukotriene B4 + 2 H+ + H2O + oxidized [NADPH-hemoprotein reductase]. [GOC:mw, PMID:2549038, PMID:2836406, PMID:9675028, RHEA:48672]
20-Aldehyde-leukotriene B4 20-monooxygenase activity is a crucial enzymatic process involved in the metabolism of leukotriene B4 (LTB4), a potent lipid mediator in inflammation and immune responses. LTB4 plays a critical role in recruiting and activating neutrophils, a type of white blood cell involved in host defense. 20-Aldehyde-leukotriene B4 20-monooxygenase, also known as leukotriene B4 20-hydroxylase, catalyzes the oxidation of the C-20 aldehyde group of LTB4 to a carboxylic acid, forming 20-COOH-LTB4. This conversion results in the inactivation of LTB4, effectively reducing its pro-inflammatory signaling activity. Specifically, the enzyme utilizes molecular oxygen (O2) and NADPH (nicotinamide adenine dinucleotide phosphate) as cofactors to facilitate the hydroxylation reaction. The mechanism involves the formation of a reactive oxygen species, such as a hydroxyl radical, which then attacks the aldehyde group of LTB4, resulting in its oxidation to a carboxylic acid. 20-Aldehyde-leukotriene B4 20-monooxygenase is thus a critical regulator of LTB4 signaling and inflammation, contributing to the resolution of inflammatory processes by limiting the activity of this potent lipid mediator.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Cytochrome P450 4F3 | A cytochrome P450 4F3 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q08477] | Homo sapiens (human) |
| Cytochrome P450 4F2 | A cytochrome P450 4F2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P78329] | Homo sapiens (human) |
| Cytochrome P450 4F3 | A cytochrome P450 4F3 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q08477] | Homo sapiens (human) |
| Cytochrome P450 4F2 | A cytochrome P450 4F2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P78329] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| 17-octadecynoic acid | octadec-17-ynoic acid : An acetylenic fatty acid that is octadecanoi acid (stearic acid) which has been doubly dehydrogenated at positions 17 and 18 to give the corresponding alkynoic acid. | acetylenic fatty acid; long-chain fatty acid; monounsaturated fatty acid; terminal acetylenic compound | EC 1.14.14.94 (leukotriene-B4 20-monooxygenase) inhibitor; EC 1.14.15.3 (alkane 1-monooxygenase) inhibitor; P450 inhibitor |
| ketoconazole | 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively. | dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine | |
| tranylcypromine | (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine. tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine). Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311) | 2-phenylcyclopropan-1-amine | |
| proadifen hydrochloride | |||
| pirlindole | pirlindole: RN given refers to parent cpd; synonym pyrazidol refers to mono-HCl; structure in Negwer, 5th ed, #2812 | carbazoles | |
| kaf156 | ganaplacide: antimalarial |